Albany Molecular Research appoints new COO and head of corporate business development

14 September 2015

Contract research and manufacturing organization Albany Molecular Research (Nasdaq: AMRI) has named George Svokos chief operating officer, and Lori Henderson head of corporate business development.

Mr Svokos joined AMRI in January 2014 from Teva Pharmaceutical Industries (NYSE: TEVA), where he was senior vice president of US Technical Operations. Ms Henderson joined the company in February 2011 from technology company Rand Worldwide.

William Marth, president and chief executive of AMRI, said: "Aligning our leadership as we grow and move forward with our strategy to be the preeminent supplier of custom and complex end-to-end services to the pharmaceutical industry will ensure AMRI's success as a whole. Both George and Lori have made significant contributions to AMRI, each demonstrating a leadership and vision, while helping navigate the complex M&A environment as the company continues to expand organically and inorganically."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK